Update
We’re hiring!
Unlocking Pharma's Potential with AI: Introducing Agent OS
A79 builds AI-powered solutions to empower your teams and drive innovation.
Update
We’re hiring!
Unlocking Pharma's Potential with AI: Introducing Agent OS
A79 builds AI-powered solutions to empower your teams and drive innovation.
Update
We’re hiring!
Unlocking Pharma's Potential with AI: Introducing Agent OS
A79 builds AI-powered solutions to empower your teams and drive innovation.
Update
We’re hiring!
Unlocking Pharma's Potential with AI: Introducing Agent OS
A79 builds AI-powered solutions to empower your teams and drive innovation.
Problem
Overcoming Pharma's Biggest Hurdles with the Power of AI.
Overcoming Pharma's Biggest Hurdles with the Power of AI.
Overcoming Pharma's Biggest Hurdles with the Power of AI.
Medical Affairs
Streamline medical information and enhance engagement with HCPs
Explore Intelligent Medical
Affairs Solutions
Regulatory Affairs
Automate submissions, accelerate approvals, and ensure compliance.
Unlock Smarter Regulatory
Processes
Commercial Affairs
Optimize launch strategies, personalize marketing, and drive sales growth.
Boost Commercial Success
with AI
Market Access
Generate evidence, develop value propositions, and secure optimal reimbursement.
Maximize Market Access
Research & Development
Identify promising targets, accelerate drug discovery, and optimize development pipelines.
AI-Powered R&D
Clinical Affairs
Accelerate trial recruitment, optimize data management, and improve study efficiency.
Coming Soon
A79
®
A79
®
unlocks new possibilities for your pharma
organization. Explore our solutions and discover how we can help you achieve your goals.
Medical Affairs
Streamline medical information and enhance engagement with HCPs
Explore Intelligent Medical
Affairs Solutions
Regulatory Affairs
Automate submissions, accelerate approvals, and ensure compliance.
Unlock Smarter Regulatory
Processes
Commercial Affairs
Optimize launch strategies, personalize marketing, and drive sales growth.
Boost Commercial Success
with AI
Market Access
Generate evidence, develop value propositions, and secure optimal reimbursement.
Maximize Market Access
Research & Development
Identify promising targets, accelerate drug discovery, and optimize development pipelines.
AI-Powered R&D
Clinical Affairs
Accelerate trial recruitment, optimize data management, and improve study efficiency.
Coming Soon
A79
®
A79
®
unlocks new possibilities for your pharma organization. Explore our solutions and discover how we can help you achieve your goals.
A79
®
unlocks new possibilities for your pharma organization.
Explore our solutions and discover how we can help you achieve your goals.
Solution
How A79 Delivers Value
A79’s intuitive conversational interface makes data analysis effortless. By automatically filtering, categorizing, and summarizing complex datasets, A79 quickly surfaces the key insights buried in your data.
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Automatic Citations
Generate accurate citations for all your data sources automatically, ensuring transparency and compliance.
Request a demo
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
AI-Powered Worksheets
Easily extract structured attributes out of unstructured data. Collaborate with AI-powered worksheets that streamline analysis and accelerate decision-making.
Advanced Filters
Drill down into your data with powerful filters that isolate specific cohorts, time frames, and variables.
Dashboards with re-usable insights
Create interactive dashboards with customizable widgets to monitor key metrics and share insights across your organization.
Configure email alerts when there are significant changes to the answers in a dashboard.
Request a demo
Pharma enterprise integrations
Seamlessly integrate with your existing pharma systems and data sources for a unified and comprehensive view.
Multi agent system
Leverage multiple AI agents, each specialized in a specific domain, to unlock deeper insights and drive holistic solutions.
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Automatic Citations
Generate accurate citations for all your data sources automatically, ensuring transparency and compliance.
Request a demo
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
AI-Powered Worksheets
Easily extract structured attributes out of unstructured data. Collaborate with AI-powered worksheets that streamline analysis and accelerate decision-making.
Advanced Filters
Drill down into your data with powerful filters that isolate specific cohorts, time frames, and variables.
Dashboards with re-usable insights
Create interactive dashboards with customizable widgets to monitor key metrics and share insights across your organization.
Configure email alerts when there are significant changes to the answers in a dashboard.
Request a demo
Add to dashboard
Product Information: LYTGOBI (Futibatinib)
Based on the information provided in the table, here's a summary of the feedback and key insights about the product LYTGOBI (Futibatinib):
Efficacy
1. Good response rates and long duration of response:
Patients have shown responses lasting >2 years
Good efficacy reported, making it a go-to option for FGFR2 fusion or gene rearrangement
Exciting response rate and longer duration of response
PFS is longer than anticipated
2. Potential for use in specific patient populations:
• May be used immediately after first-line treatment in patients unable to tolerate Cisplatin
Safety and Adverse Events
1. Nail toxicities:
Pharma enterprise integrations
Seamlessly integrate with your existing pharma systems and data sources for a unified and comprehensive view.
Multi agent system
Leverage multiple AI agents, each specialized in a specific domain, to unlock deeper insights and drive holistic solutions.
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Automatic Citations
Generate accurate citations for all your data sources automatically, ensuring transparency and compliance.
Request a demo
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
AI-Powered Worksheets
Easily extract structured attributes out of unstructured data. Collaborate with AI-powered worksheets that streamline analysis and accelerate decision-making.
Advanced Filters
Drill down into your data with powerful filters that isolate specific cohorts, time frames, and variables.
Dashboards with re-usable insights
Create interactive dashboards with customizable widgets to monitor key metrics and share insights across your organization.
Configure email alerts when there are significant changes to the answers in a dashboard.
Request a demo
Add to dashboard
Product Information: LYTGOBI (Futibatinib)
Based on the information provided in the table, here's a summary of the feedback and key insights about the product LYTGOBI (Futibatinib):
Efficacy
1. Good response rates and long duration of response:
Patients have shown responses lasting >2 years
Good efficacy reported, making it a go-to option for FGFR2 fusion or gene rearrangement
Exciting response rate and longer duration of response
PFS is longer than anticipated
2. Potential for use in specific patient populations:
• May be used immediately after first-line treatment in patients unable to tolerate Cisplatin
Safety and Adverse Events
1. Nail toxicities:
Pharma enterprise integrations
Seamlessly integrate with your existing pharma systems and data sources for a unified and comprehensive view.
Multi agent system
Leverage multiple AI agents, each specialized in a specific domain, to unlock deeper insights and drive holistic solutions.
Case studies
See A79 in Action
Discover how A79 is driving measurable productivity improvements for our partners
The platform's AI-powered insights allow us to tailor our medical communications and deliver the right information to the right audience at the right time. This has significantly improved our engagement and strengthened our relationships with key opinion leaders.
Head of Medical Affairs
Leading Pharmaceutical Company
A79 has been a true partner in our AI journey, working hand-in-hand with us to build custom solutions that are not only powerful but also incredibly user-friendly. The platform has been enthusiastically embraced by our entire team.
Head of AI development
Leading Oncology Company
A79 has completely transformed my workflow. I can now access critical scientific information, prepare for HCP interactions, and generate insightful reports in a fraction of the time it used to take.
Senior MSL
Top 20 Pharma
The platform's AI-powered insights allow us to tailor our medical communications and deliver the right information to the right audience at the right time. This has significantly improved our engagement and strengthened our relationships with key opinion leaders.
Head of Medical Affairs
Leading Pharmaceutical Company
A79 has been a true partner in our AI journey, working hand-in-hand with us to build custom solutions that are not only powerful but also incredibly user-friendly. The platform has been enthusiastically embraced by our entire team.
Head of AI development
Leading Oncology Company
A79 has completely transformed my workflow. I can now access critical scientific information, prepare for HCP interactions, and generate insightful reports in a fraction of the time it used to take.
Senior MSL
Top 20 Pharma
FAQ
FAQs
How does A79 ensure the security and confidentiality of our sensitive pharmaceutical data?
How does A79 ensure the security and confidentiality of our sensitive pharmaceutical data?
How can we validate the accuracy and reliability of A79's AI-powered insights and ensure compliance with regulatory requirements?
How can we validate the accuracy and reliability of A79's AI-powered insights and ensure compliance with regulatory requirements?
Can A79 be integrated with our existing enterprise systems
and data sources, such as LIMS, EDC, and CRM?
Can A79 be integrated with our existing enterprise systems
and data sources, such as LIMS, EDC, and CRM?
What is the expected return on investment (ROI) for implementing A79, and how can we measure its impact on our business objectives?
What is the expected return on investment (ROI) for implementing A79, and how can we measure its impact on our business objectives?
FAQ
FAQs
FAQs
How does A79 ensure the security and confidentiality of our sensitive pharmaceutical data?
How does A79 ensure the security and confidentiality of our sensitive pharmaceutical data?
How can we validate the accuracy and reliability of A79's AI-powered insights and ensure compliance with regulatory requirements?
How can we validate the accuracy and reliability of A79's AI-powered insights and ensure compliance with regulatory requirements?
Can A79 be integrated with our existing enterprise systems
and data sources, such as LIMS, EDC, and CRM?
Can A79 be integrated with our existing enterprise systems
and data sources, such as LIMS, EDC, and CRM?
What is the expected return on investment (ROI) for implementing A79, and how can we measure its impact on our business objectives?
What is the expected return on investment (ROI) for implementing A79, and how can we measure its impact on our business objectives?
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Get in touch
Request a demo
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Get in touch
Request a demo
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
A79
®
Copyright A79® 2024
A79
®
Copyright A79® 2024